Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

By sjmartinez • October 19, 2023

Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. PMID: 37855026; PMCID: PMC10579289.

Tags: ACTIV-2, covid-19, Infectious Diseases, Inhaled interferon, Publications, Randomized clinical trial, SARS-CoV-2

Comparing generative artificial intelligence vs. experts for detection of catheter-associated urinary tract infection (CAUTI)

Alshanqeeti S, Coffey K, Mcdermott K, de Guzman A, Branch-Elliman W, Goodman KE, Harris AD, Baghdadi J, Morgan DJ. Comparing generative artificial intelligence vs. experts[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]

Prophage-encoded virulence factor, Gp05, contributes to endothelial cell dysfunction and immune evasion to promote persistent methicillin-resistant Staphylococcus aureus endovascular infections

Li Y, Manna AC, Ibrahim S, Proctor RA, Cheung AL, Xiong YQ. Prophage-encoded virulence factor, Gp05, contributes to endothelial cell dysfunction and immune evasion to[...]